Onkologie Donauwoerth (MVZ) GmbH
- Address
- Hochstrasse 27, 85221 Donauwörth, Germany
Cardiovascular Diseases
At Onkologie Donauwoerth (MVZ) GmbH, investigators are extending their expertise to cardiovascular research, integrating cardiovascular safety monitoring into oncology studies.
- Cardiac function assessment in patients receiving novel cancer therapies
- Evaluation of biomarkers for heart failure risk
The facility hosts two active trials and a team of two investigators, combining oncology and supportive cardio‑oncology care.
Hemic and Lymphatic Diseases
The centre’s focus on blood‑related disorders is highlighted by a trial targeting Multiple Myeloma, aiming to improve deep remission rates.
- MRD‑negativity combined with ≥CR as primary endpoint
- Flow cytometry and next‑generation sequencing for disease monitoring
Through the ELIAS study, researchers evaluate first‑line therapies to achieve sustained disease control.
Immune System Diseases
Research at the site explores immune modulation, exemplified by a combination study of olomorasib with immune checkpoint inhibitors in lung cancer.
- Combination with pembrolizumab versus placebo
- Combination with durvalumab versus placebo
- Assessing synergistic anti‑tumor immunity
The SUNRAY‑02 trial investigates how targeting KRAS G12C enhances immune response in KRAS G12C‑mutant Non‑Small Cell Lung Cancer.
Neoplasms
Onkologie Donauwoerth (MVZ) GmbH conducts cutting‑edge cancer trials, covering both hematologic and solid tumours.
- Expression‑linked stratification for first‑line therapy in Multiple Myeloma
- Olomorasib plus standard of care in KRAS G12C‑mutant NSCLC
- Evaluation of minimal residual disease as a surrogate endpoint
With two investigators overseeing two studies, the centre aims to advance therapeutic options across the oncology spectrum.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Onkologie Donauwoerth (MVZ) GmbH
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Randomized phase II trial for patients with newly diagnosed low-risk multiple myeloma to evaluate the benefit of 6 cycles of isatuximab with lenalidomide/bortezomib/dexamethasone (I-VRD) followed by maintenance therapy with lenalidomide and isatuximab randomized in comparison with therapy consisting of 3 cycles of I-VRD followed by one cycle of high-dose therapy and maintenance therapy with lenalidomide and isatuximab | Universitaetsklinikum Schleswig-Holstein AöR | Phase II | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Betamethasone Sodium Phosphate Ph. Eur | 1 | Unknown | 2023-10-30 | 2023-10-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.